Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Doxorubicin and Selenium Cooperatively Induce Fas Signaling in the Absence of Fas/Fas Ligand Interaction

SONG LI, YUNFEI ZHOU, YAN DONG and CLEMENT IP
Anticancer Research September 2007, 27 (5A) 3075-3082;
SONG LI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUNFEI ZHOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YAN DONG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CLEMENT IP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: clement.ip@roswellpark.org
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 27 no. 5A 3075-3082
PubMed 
17970047

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received July 25, 2007
  • Accepted August 6, 2007
  • Published online September 1, 2007.

Copyright & Usage 
Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. SONG LI1,
  2. YUNFEI ZHOU2,
  3. YAN DONG1 and
  4. CLEMENT IP1
  1. 1Department of Cancer Chemoprevention, Roswell Park Cancer Institute, Buffalo, NY 14263
  2. 2Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, U.S.A.
  1. Correspondence to: Clement Ip, Ph.D., Department of Cancer Chemoprevention, Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, U.S.A. Tel: +1 716 845 8875, Fax: +1 716 845 8100, e-mail: clement.ip{at}roswellpark.org

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research: 27 (5A)
Anticancer Research
Vol. 27, Issue 5A
September-October 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Doxorubicin and Selenium Cooperatively Induce Fas Signaling in the Absence of Fas/Fas Ligand Interaction
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Doxorubicin and Selenium Cooperatively Induce Fas Signaling in the Absence of Fas/Fas Ligand Interaction
SONG LI, YUNFEI ZHOU, YAN DONG, CLEMENT IP
Anticancer Research Sep 2007, 27 (5A) 3075-3082;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Doxorubicin and Selenium Cooperatively Induce Fas Signaling in the Absence of Fas/Fas Ligand Interaction
SONG LI, YUNFEI ZHOU, YAN DONG, CLEMENT IP
Anticancer Research Sep 2007, 27 (5A) 3075-3082;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Selenoesters and Selenoanhydrides as Novel Agents Against Resistant Breast Cancer
  • Uptake and Efflux of Rhenium in Cells Exposed to Rhenium Diseleno-Ether and Tissue Distribution of Rhenium and Selenium After Rhenium Diseleno-Ether Treatment in Mice
  • Prevention of Carboplatin-induced Resistance in Human Ovarian Tumor Xenografts by Selenite
  • Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex
  • Resistance to chemotherapy and hormone therapy in endometrial cancer
  • Google Scholar

More in this TOC Section

  • MAP17 as a Mediator of HGF-induced Proliferation and Invasion in Gastric Cancer
  • Contribution of Methylenetetrahydrofolate Reductase Genotypes to Brain Tumor Risk Determination in Taiwan
  • Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Reduces Aggressiveness of Cervical Carcinoma Cells
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire